EUCTR2007-004699-38-DE进行中（未招募）不适用
A prospective phase I/II, one-arm, multi-center, open label study of pioglitazone in combination with sorafenib and low dose IFN alphain metastatic, non-resectable renal clear cell carcinoma
Klinikum der Universität Regensburg0 个研究点开始时间: 2007年11月5日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients with advanced renal clear cell carcinoma
- •-who have failed prior cytokine-based therapy but are considered suitable for combination therapy with low dose cytokine-based therapy as planned in this study or
- •-who are unsuitable for full dose cytokine-based therapy but are considered suitable for combination therapy with low dose cytokine-based therapy as planned in this study
- •At least 18 years of age
- •Sufficient bone marrow function: neutrophils ? 2 x 109/l, hemoglobin = 10 g/dl, and platelets ? 100 x 109/l
- •Performance status ECOG 0-1
- •Required laboratory results:
- •a) Liver function: Total bilirubin ? 1.5 x ULN, SGPT, SGOT ? 2.5 x ULN.
- •b) Renal function: serum creatinine ? 1.5 x ULN
- •c) PT-INR/PT ? 1.5 x ULN
- •Normal cardiac function
- •Life expectancy at least 3 months
- •Written informed consent of the patient prior to screening procedures
- •Patient must be available for treatment and follow-up
- •Any previous surgery must have taken place more than 4 weeks prior to inclusion
- •Previous radiation therapy must have involved less than 25% of bone marrow and must have been completed more than 4 weeks prior to inclusion.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients who require vitamin K antagonists except for low dose
- •Active infection > grade 2 CTCAE version 3.0
- •Known diagnosis of HIV, hepatitis B, or hepatitis C infection.
- •Severe, unstable, or uncontrolled medical disease which would confound diagnoses or evaluations required by the protocol, including cardiac insufficiency (NYHA I–IV) ), symptomatic coronary artery disease, prior myocardial infarction, cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted), uncontrolled hypertension, uncontrolled diabetes, chronic hepatic or renal disease, active uncontrolled infection and chronic inflammatory intestinal disease, auto-immune diseases.
- •Prior radiation therapy > 25% of bone marrow
- •Clinically symptomatic brain metastases
- •Regular blood transfusions
- •Treatment with other experimental substances within 30 days before study start
- •Participation in another clinical trial within 30 days before study start or during the trial
- •Unwilling or unable to comply with the protocol
- •Pregnant or breastfeeding patients. Women of childbearing potential must have a negative pregnancy test performed 7 days prior start of treatment
- •Women of child-bearing potential, men with reproductive potential enrolled in this trial must use adequate barrier birth control measures during the course of the trial contraception. Men should use adequate birth control for at least three months after the administration of sorafenib
- •Patients with seizure disorders requiring medication (such as steroids or antiepileptics)
- •Known hypersensitivity to one of the medications
- •Patients with evidence or history of bleeding diathesis
- •Patients undergoing renal dialysis
- •Major surgery within 4 weeks prior to start of study or incomplete wound healing
- •Drug or alcohol abuse
- •Psychological or social conditions that may interfere with the patients participation in the study or evaluation of the study results
- •Known (at time of entry) gastrointestinal disorder, including malabsorbtion or active gastric ulcer, present to the extent that it might interfere with oral intake and absorption of study medication
- •Any previous or concurrent malignancy or any cancer unless curatively treated > 3 years prior to study entry except cervical carcinoma in situ or adequately treated basal cell carcinoma.
研究者
相似试验
招募中
1 期
CAR-T cells Therapy in ALL patientsRelapsed or refractory B cell malignanciesB-ALLCAR-T cellsCell TherapyTCTR20220624004Genepeutic Bio, Co., Ltd20
进行中（未招募）
1 期
The study will evaluate the safety and efficacy of a combined therapy consisting of immuntherapy and radiation prior to radical cystectomy in patients with locally advanced urothelial bladder cancerEUCTR2018-001823-38-DETechnische Universität München, Fakultät für Medizin vertreten durch den Dekan33
进行中（未招募）
1 期
A prospective phase I/II, one-arm, one-stage multi-center, open label study of lenalidomide in combination with pioglitazone, dexamethasone and metronomic low-dose chemotherapy with treosulfan in patients with relapsed or refractory or progressive multiple myeloma: Third-line therapyMultiple myelomaEUCTR2008-002768-32-DEFreistaat Bayern54
已完成
2 期
A prospective, multi-centre, single arm, phase 2 assessment of the efficacy and safety of the combination of ixazomib, thalidomide and dexamethasone (ITD) for relapsed and/or refractory multiple myeloma after 1 to 3 prior lines of therapy.Cancer - MyelomaMultiple MyelomaACTRN12616000894493Professor Andrew Spencer40
进行中（未招募）
1 期
Safety evaluation of neoadjuvant Myocet® plus paclitaxel, trastuzumab, and pertuzumab in patients with operable HER2-positive breast cancerHER2-positive breast cancerMedDRA version: 14.1Level: LLTClassification code 10065430Term: HER-2 positive breast cancerSystem Organ Class: 100000004864EUCTR2012-001201-24-ESSOLTI83